Funding for this research was provided by:
Yuekang Pharmaceutical Co., Ltd (HX-G19-050)
Article History
Received: 3 December 2019
Accepted: 7 June 2020
First Online: 19 June 2020
Ethics approval and consent to participate
: This trial protocol has been reviewed and approved by Biomedical Ethics Committee of West China Hospital of Sichuan University on 24 December 2018 (No. 11). After the general research center obtained the ethics approval, each participating center has obtained the ethics approval in the corresponding Ethics Committee. Participants should give written, informed, and voluntary consent before recruitment.
: Not applicable.
: The study is funded by Yuekang Pharmaceutical Co., Ltd (Beijing, China). The authors declare that there is no other conflict of interests.